Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Parmaceuticals (RCE) has been granted ethics approval to start a phase one/two study on patients with infected burn wounds
  • The trial will test a spray-on formulation of candidate drug, RECCE 327, which is a broad-spectrum synthetic polymer antibiotic
  • Recce anticipates the study will be sponsored by WA's South Metropolitan Health Service, with Fiona Stanley Hospital nominated as the study site
  • A previously announced intravenous study will run in parallel to demonstrate the broad administration capabilities of RECCE 327
  • Recce 327 is being developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms
  • Recce Pharmaceuticals is trading 4.72 per cent higher for $1.11

Recce Parmaceuticals (RCE) has been granted ethics approval to start a phase one/two study on patients with infected burn wounds.

The trial will test the company's drug candidate, RECCE 327, which is a broad-spectrum synthetic polymer antibiotic.

The trial

The study will assess the safety and efficacy of RECCE 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two weeks.

10 patients will receive the drug daily, while a further 20 will receive treatment three times per week.

Recce anticipates the study will be sponsored by WA's South Metropolitan Health Service, with Fiona Stanley Hospital nominated as the study site.

Investigators will review the study data for clinical efficacy and toxicity before deciding to expand the trial to phase two to test the compound against the current best standards of care.

The drug will be delivered via a specially developed spray-on formulation, which was manufactured at Recce's facility.

Outlook

A previously announced intravenous study will run in parallel to demonstrate the broad administration capabilities of RECCE 327.

Recce Pharmaceuticals Chairman Dr John Prendergast says gaining Human Research Ethics Committee (HREC) approval is an important step.

"Human ethics approval is another milestone for Recce and the clinicians seeking effective treatments to combat the scourge of antibiotic resistant bacteria," the Chairman said.

"Achieving this goal speaks to the dedication of our clinical and research team as we continue to build on our clinical and commercial potential," he concluded.

Recce 327 is being developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria — including their superbug forms.

The company is working towards developing new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce Pharmaceuticals is trading 4.72 per cent higher for $1.11 at 10:43 am AEDT.

RCE by the numbers
More From The Market Herald
Oventus Medical (ASX:OVN) - Chairman, Sue MacLeman (centre left) - The Market Herald

" Oventus Medical (ASX:OVN) eyes $5M placement to strengthen balance sheet

Sleep apnoea specialist Oventus Medical (OVN) has received firm commitments to undertake a $5 million placement.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trial

Telix Pharmaceuticals (TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in
Bod Australia (ASX:BDA) - CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) records highest ever month of MediCabilis sales

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.